ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

CGTX Cognition Therapeutics Inc

1.99
0.00 (0.00%)
Pre Mercado
Última actualización: 03:05:19
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Cognition Therapeutics Inc CGTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 1.99 03:05:19
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.99
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/3/202415:11EDGAR2Form 8-K - Current report
11/3/202415:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202415:44EDGAR2Form 8-K - Current report
20/2/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202414:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
08/1/202415:11EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
04/1/202415:21EDGAR2Form 8-K - Current report
04/1/202406:30GLOBECognition Therapeutics CEO Issues Letter to Shareholders
29/12/202315:02EDGAR2Form S-3 - Registration statement under Securities Act of..
16/11/202306:30GLOBECognition Therapeutics Releases New Episode of..
15/11/202306:30GLOBECognition Therapeutics Presents Preclinical Data Identifying..
13/11/202316:25EDGAR2Form SC 13D/A - General statement of acquisition of..
13/11/202308:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202308:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202306:30GLOBECognition Therapeutics Completes Enrollment in Phase 2 SHINE..
02/11/202306:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202306:41EDGAR2Form 8-K - Current report
02/11/202306:30GLOBECognition Therapeutics Reports Third Quarter 2023 Financial..
27/10/202306:30GLOBECognition Therapeutics and Collaborators at Yale and ACTC..
24/10/202315:30GLOBECognition Therapeutics Presents Complete EEG Findings from..
16/10/202306:30GLOBECognition Therapeutics Presents New Data at CTAD Conference..
12/9/202306:00EDGAR2Form 8-K - Current report
07/9/202306:45GLOBECognition Therapeutics Announces New Conversations Episode..
30/8/202307:00GLOBECognition Therapeutics Announces Participation in Upcoming..
24/8/202306:00EDGAR2Form 8-K - Current report
08/8/202306:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:05EDGAR2Form 8-K - Current report
08/8/202306:00GLOBECognition Therapeutics Reports Second Quarter 2023 Financial..
02/8/202306:30GLOBECognition Therapeutics to Report Second Quarter 2023 Results..
11/7/202306:30GLOBECognition Therapeutics Announces Dosing of First Patient in..
05/7/202306:30GLOBECognition Therapeutics and the Alzheimer's Clinical Trials..
28/6/202306:00GLOBECognition Therapeutics Announces Positive Topline Results..
27/6/202318:17GLOBECognition Therapeutics to Host Call and Webcast to Discuss..
20/6/202306:30GLOBECognition Therapeutics Invited to Participate on Panel..
02/6/202306:30GLOBECognition Therapeutics Continues Investor Engagement in June..
23/5/202306:30GLOBECognition Therapeutics Latest Episode of “Conversations”..
18/5/202306:30GLOBECognition Therapeutics Publishes Clinical Evidence that..

Su Consulta Reciente

Delayed Upgrade Clock